NCT03819322View on ClinicalTrials.gov

The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 15, 2019

Primary Completion Date

March 17, 2025

Study Completion Date

March 17, 2025

Conditions
Liver TransplantHepatitis C
Interventions
DRUG

sofosbuvir/velpatasvir

12 week, oral, fixed dose

Trial Locations (1)

15213

UPMC, Pittsburgh

All Listed Sponsors
collaborator

University of Pittsburgh Medical Center

OTHER

lead

Fernanda P Silveira, MD, MS

OTHER

NCT03819322 - The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients | Biotech Hunter | Biotech Hunter